EP2353618A2 - Charge différentielle de dispositifs médicaux pour élution de médicaments - Google Patents

Charge différentielle de dispositifs médicaux pour élution de médicaments Download PDF

Info

Publication number
EP2353618A2
EP2353618A2 EP11250117A EP11250117A EP2353618A2 EP 2353618 A2 EP2353618 A2 EP 2353618A2 EP 11250117 A EP11250117 A EP 11250117A EP 11250117 A EP11250117 A EP 11250117A EP 2353618 A2 EP2353618 A2 EP 2353618A2
Authority
EP
European Patent Office
Prior art keywords
bioactive agent
substrate
medical device
central portion
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP11250117A
Other languages
German (de)
English (en)
Other versions
EP2353618A3 (fr
EP2353618B1 (fr
Inventor
Daniel Broom
Joshua Stopek
Amin Elachchabi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Covidien LP
Original Assignee
Tyco Healthcare Group LP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tyco Healthcare Group LP filed Critical Tyco Healthcare Group LP
Publication of EP2353618A2 publication Critical patent/EP2353618A2/fr
Publication of EP2353618A3 publication Critical patent/EP2353618A3/fr
Application granted granted Critical
Publication of EP2353618B1 publication Critical patent/EP2353618B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/0063—Implantable repair or support meshes, e.g. hernia meshes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/44—Medicaments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/402—Anaestetics, analgesics, e.g. lidocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/45—Mixtures of two or more drugs, e.g. synergistic mixtures
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/602—Type of release, e.g. controlled, sustained, slow

Definitions

  • the present disclosure relates to drug delivering medical devices. More particularly, the present disclosure relates to medical and/or surgical implants having a drug dose concentration gradient imparted thereto, and methods of forming and using the same, for tailored localized drug delivery to tissue within a surgical site.
  • Surgical implants such as drug eluting devices, are known to serve as vehicles for the delivery of drugs or other therapeutics.
  • devices such as stents, are coated with a biologically active agent to provide treatment to an implant site. It is generally desirable that an effective therapeutic amount of a selected drug be released from the device at a certain rate for an extended period of time.
  • the release of the drug from the coating medium may be dependent upon the nature of the coating material and the drug that is incorporated therein, with drug release occurring by diffusion through the coating material or with degradation of the coating material.
  • implants such as meshes
  • implants are generally customized and cut to a desired size based on anatomical need.
  • any cutting or trimming of a drug-eluting implant may affect the drug payload of the device.
  • a medical device in accordance with the present disclosure includes a central portion and a peripheral portion having a concentration gradient of a first bioactive agent between the central and peripheral portions.
  • the gradient increases in concentration from the central portion to the peripheral portion. In other embodiments, the gradient increases in concentration from the peripheral portion to the central portion of the medical device.
  • a medical device includes a substrate having at least one surface.
  • the surface has a central portion and a peripheral portion.
  • a first bioactive agent is disposed over at least a portion of the surface.
  • a higher concentration of the first bioactive agent is positioned on the central portion of the substrate and a lower concentration of the first bioactive agent extends outwardly from the central portion to the peripheral portion of the substrate.
  • the bioactive agent may extend through the peripheral portion of the surface of the substrate.
  • the substrate includes an intermediate portion positioned between the central portion and the peripheral portion, in which the lower concentration of the bioactive agent is disposed.
  • the bioactive agent may be disposed on the surface of the substrate as a substantially continuous concentration gradient, or alternatively, as a discontinuous concentration gradient.
  • the intermediate portion includes successive sections separately extending away from the central portion, wherein the bioactive agent decreases in concentration through each successive section towards the peripheral portion of the substrate.
  • the successive sections in embodiments, may be annular rings which are concentric to the central portion of the substrate. In other embodiments, the successive sections may be bands longitudinally aligned with the central portion of the substrate.
  • the bioactive agent may be disposed, for example, within the materials which form the medical device, or the bioactive agents may be disposed in a coating composition, polymeric film, foam, or encapsulated within a polymeric material in a flowable state.
  • the intermediate portion of the substrate includes a plurality of polymeric capsules containing the bioactive agent in a flowable state.
  • the substrate may include a concentration gradient of the bioactive agent in a height dimension of the substrate.
  • the bioactive agent may be disposed within pores of the substrate thereby creating a concentration gradient in the height dimension.
  • the substrate may include a lower concentration of a first bioactive agent on a central portion of the substrate, while a higher concentration of the second bioactive agent extends outwardly from the central portion towards the peripheral portion of the substrate.
  • the first bioactive agent may be different than the second bioactive agent.
  • the lower concentration may be more therapeutically effective compared to the higher concentration.
  • the first or second bioactive agents may comprise capsaicin, bupivacaine or bupivacaine hydrochloride.
  • the medical device may also include markings on the substrate for visualization of the bioactive agent.
  • FIGURE 1 schematically shows a medical device having a substantially continuous gradient of a bioactive agent over a surface of the medical device in accordance with an embodiment of the present disclosure
  • FIGURE 2 schematically shows a medical device having a substantially continuous gradient of a bioactive agent over a portion of a surface of the medical device in accordance with another embodiment of the present disclosure
  • FIGURE 3 schematically shows a medical device having a discontinuous gradient of a bioactive agent in accordance with one embodiment of the present disclosure
  • FIGURE 4 schematically shows a medical device having a discontinuous gradient of a bioactive agent in accordance with another embodiment of the present disclosure
  • FIGURE 5 schematically shows a medical device having a discontinuous gradient of a bioactive agent in accordance with yet another embodiment of the present disclosure
  • FIGURE 6 schematically shows a medical device having a gradient of a bioactive agent in a height dimension in accordance with an embodiment of the present disclosure
  • FIGURE 7 schematically shows a medical device having a discontinuous gradient of a bioactive agent in accordance with yet another embodiment of the present disclosure
  • FIGURE 8 schematically shows a medical device having a substantially continuous gradient of a bioactive agent as well as orientation lines and markings in accordance with an embodiment of the present disclosure
  • FIGURE 9 schematically shows a medical device having a discontinuous gradient of a bioactive agent as well as orientation lines and markings in accordance with another embodiment of the present disclosure.
  • FIGURE 10 schematically shows a medical device having a concentration gradient of a bioactive agent in accordance with an alternate embodiment of the present disclosure.
  • Medical devices in accordance with the present disclosure include a substrate upon, or within, which desired bioactive agent(s) may be applied to, or otherwise loaded therein or therethrough, for therapeutic treatment of tissue.
  • the medical device may be any surgical implant, such as meshes, (tissue) scaffolds, grafts, stents, sutures, patches, slings, buttresses, pledgets, soft tissue repair devices, and in general, any mechanical, electrical or digital implants.
  • Some other non-limiting examples include soft tissue repair devices, surgical prostheses, and artificial organs; or topically applied medical products, such as wound dressings, coverings, tapes, gauzes, and the like, that can be used in medical/surgical procedures.
  • the medical device may include pores or openings on at least a portion of a surface thereof, within which the bioactive agent(s) may be disposed.
  • the pores may be present as a surface characteristic or a bulk material property, which partially or completely penetrates the medical device, and may be uniformly distributed across portions thereof.
  • the medical device may have an open-cell structure, where the pores are connected to each other, forming an interconnected network. Conversely, the medical device may be closed cell, where the pores are not interconnected.
  • pores may be created using any method within the purview of those skilled in the art including, but not limited to, lyophilization or freeze-drying, sintering, leaching of salt, and sugar or starch crystals.
  • openings may be formed in filamentous medical devices, such as sutures and meshes, via the spaces formed between the filaments.
  • bioactive agent which is disposed on at least a portion of the medical device.
  • the bioactive agent may be in the form of a single coating, or multiple coatings. The coatings of course may be continuous or discontinuous.
  • the bioactive agent may be coated on, or impregnated in, a medical device of the present disclosure to provide specific biological or therapeutic properties thereto.
  • bioactive agent as used herein, is used in its broadest sense and includes any substance or mixture of substances that have clinical use. Consequently, bioactive agents may or may not have pharmacological activity per se, e.g., a dye.
  • a bioactive agent could be any agent which provides a therapeutic or prophylactic effect; a compound which may be used as a diagnostic aid; a compound that affects or participates in tissue growth, cell growth and/or cell differentiation; a compound that may be able to invoke or prevent a biological action such as an immune response; or a compound that could play any other role in one or more biological processes.
  • any agent which may enhance tissue repair or tissue integration, limit the risk of sepsis, modulate the mechanical properties of the medical device, and/or deliver pharmaceutical agents may be incorporated to the device.
  • a single bioactive agent may be utilized or, in alternate embodiments, a variety of bioactive agents may be incorporated into the medical devices of the present disclosure.
  • a first bioactive agent may be disposed on at least a portion of the medical device in a manner which creates a concentration gradient from the central portion of the medical device extending outwardly towards the peripheral portion of the medical device. It is envisioned that any number of additional bioactive agents may also be disposed on the medical devices. It is further envisioned that the additional bioactive agents may be positioned in any concentration and on any portion of the medical devices.
  • bioactive agents examples include, for example, anti-adhesives, antimicrobials, analgesics, antipyretics, anesthetics (e.g. local, regional, and systemic), antiepileptics, antihistamines, anti-inflammatories, cardiovascular drugs, diagnostic agents, sympathomimetics, cholinomimetics, antimuscarinics, antispasmodics, hormones, growth factors, muscle relaxants, adrenergic neuron blockers, antineoplastics, immunogenic agents, immunosuppressants, gastrointestinal drugs, diuretics, steroids, lipids, phosphoryl cholines, lipopolysaccharides, polysaccharides, platelet activating drugs, clotting factors, and enzymes. It is also intended that combinations of bioactive agents may be used.
  • bioactive agents which may be included as a bioactive agent include: anti-fertility agents; parasympathomimetic agents; psychotherapeutic agents; tranquilizers; decongestants; sedative hypnotics; sulfonamides; sympathomimetic agents; vaccines; vitamins; antimalarials; anti-migraine agents; anti-parkinson agents such as L-dopa; anti-spasmodics; anticholinergic agents (e.g., oxybutynin); antitussives; bronchodilators; cardiovascular agents, such as coronary vasodilators and nitroglycerin; alkaloids; analgesics; narcotics such as codeine, dihydrocodeinone, meperidine, morphine and the like; non-narcotics, such as salicylates, aspirin, acetaminophen, d-propoxyphene and the like; opioid receptor antagonists, such as naltrexone and
  • bioactive agents which may be included in the medical device include, for example, viruses and cells; peptides, polypeptides and proteins, as well as analogs, muteins, and active fragments thereof; immunoglobulins; antibodies; cytokines (e.g., lymphokines, monokines, chemokines); blood clotting factors; hemopoietic factors; interleukins (e.g., IL-2, IL-3, IL-4, IL-6); interferons (e.g., ⁇ -IFN, ⁇ -IFN and ⁇ -IFN); erythropoietin; nucleases; tumor necrosis factor; colony stimulating factors (e.g., GCSF, GM-CSF, MCSF); insulin; anti-tumor agents and tumor suppressors; blood proteins such as fibrin, thrombin, fibrinogen, synthetic thrombin, synthetic fibrin, synthetic fibrinogen; gonadotropins (e.g., FSH
  • the bioactive agent may include at least one of the following drugs, including combinations and alternative forms of the drugs such as alternative salt forms, free acid form, free base forms, pro-drugs and hydrates.
  • drugs including combinations and alternative forms of the drugs such as alternative salt forms, free acid form, free base forms, pro-drugs and hydrates.
  • Specific agents within these classes are within the purview of those skilled in the art and are dependent upon such factors as, for example, the type of device in which it is utilized and the tissue being treated.
  • local anesthetics such as bupivacaine (which may be sold under MarcainTM, MarcaineTM, SensorcaineTM and VivacaineTM all by AstraZeneca), levobupivacaine (sold under ChirocaineTM by AstraZeneca), ropivacaine, lidocaine, eand the like, may be used alone or in combination for treatment of pain or for anesthetic purposes.
  • bupivacaine which may be sold under MarcainTM, MarcaineTM, SensorcaineTM and VivacaineTM all by AstraZeneca
  • levobupivacaine sold under ChirocaineTM by AstraZeneca
  • ropivacaine lidocaine
  • eand the like may be used alone or in combination for treatment of pain or for anesthetic purposes.
  • antimicrobial agents such as triclosan, also known as 2,4,4'-trichloro-2'-hydroxydiphenyl ether; chlorhexidine and its salts, including chlorhexidine acetate, chlorhexidine gluconate, chlorhexidine hydrochloride, and chlorhexidine sulfate; silver and its salts, including silver acetate, silver benzoate, silver carbonate, silver citrate, silver iodate, silver iodide, silver lactate, silver laurate, silver nitrate, silver oxide, silver palmitate, silver protein, and silver sulfadiazine; polymyxin; tetracycline; aminoglycosides such as tobramycin and gentamicin; rifampicin; bacitracin; neomycin; chloramphenicol; miconazole; quinolones such as oxolinic acid, norfloxacin, nalidixic acid, pefloxacin, enox
  • antimicrobial proteins and peptides such as lactoferrin and lactoferricin B, and antimicrobial polysaccharides, such as fucans and derivatives thereof, may be included as a bioactive agent in the present disclosure to kill or prevent microbial growth.
  • anti-adhesive agents may be used to prevent adhesions from forming between the coated medical device and the surrounding tissues.
  • these agents include, but are not limited to, poly(vinyl pyrrolidone), carboxymethyl cellulose, hyaluronic acid, alginate, collagen, polyethylene glycol, polyethylene oxide, polypropylene glycol, poly vinyl alcohols, poly acrylic acid, styrene sulfonic acid, polyhydroxyethylmethylacrylate, (pHEMA) and phospholipid vinyls; acrylic polymers such as sodium polyacrylate, polyethylacrylate, and polyacrylamide, polypropylene oxide, phosphorylcholine functional acrylates and methacrylates; homopolymers and combinations thereof.
  • the bioactive agent(s) may be incorporated into or onto the medical device by coating a surface of the device, or portion thereof, in a variety of ways.
  • the bioactive agents may be applied via polymer coating, dry coating, freeze drying, and ionically, covalently, or affinity binding to a surface thereof.
  • a coating may be applied to the medical device utilizing any suitable method known to those skilled in the art. Some examples include, but are not limited to, spraying, dipping, layering, casting, calendering, etc.
  • one or more bioactive agents may be applied to a medical device as a composition or coating dispersed in a suitable biocompatible solvent. Suitable solvents for particular bioactive agents are within the purview of those skilled in the art.
  • a bioactive agent such as bupivacaine may be combined with a chlorinated solvent such as methylene chloride.
  • one or more bioactive agents may be combined with a biodegradable polymer which releases the bioactive agent(s) during degradation of the polymer.
  • the bioactive agents may be freely admixed with the polymeric material or may be tethered to the polymer through any suitable chemical bonds.
  • the therapeutic agent may include at least one of the following drugs, including combinations and alternative forms of the drugs such as alternative salt forms, free acid form, free base forms, pro-drugs and hydrates:
  • one or more bioactive agents may be encapsulated within a polymeric material in a flowable, or non-solid, state.
  • the polymeric material may be rapidly bioerodible, or otherwise penetrable, to provide quick release of the bioactive agent(s) into the surrounding tissue.
  • biodegradable as used herein is defined to include both bioabsorbable and bioresorbable materials.
  • biodegradable it is meant that the material decomposes, or loses structural integrity under body conditions (e.g., enzymatic degradation or hydrolysis) or is broken down (physically or chemically) under physiologic conditions in the body such that the degradation products are excretable or absorbable by the body.
  • body conditions e.g., enzymatic degradation or hydrolysis
  • physiologic conditions e.g., enzymatic degradation or hydrolysis
  • degradation products are excretable or absorbable by the body.
  • such materials include natural, synthetic, bioabsorbable, and/or non-absorbable materials, as well as combinations thereof.
  • Representative natural biodegradable polymers which may be used with the bioactive agent include: poly(amino acids) including proteins such as collagen (I, II and III), elastin, fibrin, fibrinogen, silk, and albumin; peptides including sequences for laminin and fibronectin (RGD); polysaccharides such as hyaluronic acid (HA), dextran, alginate, chitin, chitosan, cellulose, fucans, glycosaminoglycans, and chemical derivatives thereof (substitutions and/or additions of chemical groups, for example, alkyl, alkylene, hydroxylations, oxidations, and other modifications routinely made by those skilled in the art); gut; and copolymers and blends thereof, alone or in combination with synthetic polymers.
  • Collagen as used herein includes natural collagen such as animal derived collagen, gelatinized collagen, or synthetic collagen such as human or bacterial recombinant collagen.
  • Synthetically modified natural polymers include cellulose derivatives, such as alkyl celluloses, hydroxyalkyl celluloses, cellulose ethers, cellulose esters, nitrocelluloses, and chitosan.
  • suitable cellulose derivatives include methyl cellulose, ethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, hydroxybutyl methyl cellulose, cellulose acetate, cellulose propionate, cellulose acetate butyrate, cellulose acetate phthalate, carboxymethyl cellulose, cellulose triacetate, and cellulose sulfate sodium salt.
  • Representative synthetic biodegradable polymers include polyhydroxy acids prepared from lactone monomers, such as glycolide, lactide, caprolactone, ⁇ -caprolactone, valerolactone, and ⁇ -valerolactone, as well as carbonates (e.g., trimethylene carbonate, tetramethylene carbonate, and the like), dioxanones (e.g., 1,4-dioxanone and p-dioxanone), 1,dioxepanones (e.g., 1,4-dioxepan-2-one and 1,5-dioxepan-2-one), and combinations thereof.
  • lactone monomers such as glycolide, lactide, caprolactone, ⁇ -caprolactone, valerolactone, and ⁇ -valerolactone
  • carbonates e.g., trimethylene carbonate, tetramethylene carbonate, and the like
  • dioxanones e.g., 1,4-dio
  • Polymers formed therefrom include: poly(lactic acid); poly(glycolic acid); poly(trimethylene carbonate); poly(dioxanone); poly(hydroxybutyric acid); poly(hydroxyvaleric acid); poly(lactide-co-( ⁇ -caprolactone-)); poly(glycolide-co-( ⁇ -caprolactone)); poly(lactic-co-glycolic acid); polycarbonates; poly(pseudo amino acids); poly(amino acids); poly(hydroxyalkanoate)s; polyalkylene oxalates; polyoxaesters; polyanhydrides; polyortho esters; and copolymers, block copolymers, homopolymers, blends, and combinations thereof.
  • biodegradable materials include: aliphatic polyesters; polyethylene glycols; glycerols; copoly (ether-esters); and copolymers, block copolymers, homopolymers, blends, and combinations thereof.
  • Rapidly bioerodible polymers such as poly(lactide-co-glycolide)s, polyanhydrides, and polyorthoesters, which have carboxylic groups exposed on the external surface as the surface of the polymer erodes, may also be used.
  • the bioactive agent may be released into the body within a period of time ranging from about 1 second to about 21 days following implantation. In one embodiment, the agent may be released within about 1 minute to about 14 days following implantation.
  • the rate of release of a bioactive agent from the coating may be controlled by various methods. Some examples include, but are not limited to, the depth of the bioactive agent from the surface of the coating; the size of the bioactive agent; the hydrophilicity or lipophilicity of the bioactive agent; the molecular structure of the bioactive agent; the pH and/or the ionization of the agent/coating; and the strength of physical and physical-chemical interaction between the bioactive agent, the coating composition, and/or the medical device material. By properly controlling some of these factors, a controlled release of a bioactive agent from the medical device of the present disclosure can be achieved.
  • FIGURE 1 illustrates a medical device in the form of a mesh 10, according to an embodiment of the present disclosure.
  • Mesh 10 may be in the form of a plurality of fibers (not shown) defining a longitudinal length "L" and a lateral, transverse width "W".
  • Mesh 10 includes a bioactive agent 12 coated over the surface of the mesh 10.
  • Central portion 14 of mesh 10 includes the highest concentration of bioactive agent 12, which gradually decreases, or tapers off, to the peripheral portion 16 of mesh 10 through intermediate portion 18.
  • the bioactive agent 12 is disposed on mesh 10 in a substantially continuous gradient from a higher concentration at the central portion 14 of the mesh 10, to a lower concentration at the peripheral portion 16 of the mesh 10.
  • the ratio of the bioactive agent concentration from the central portion 14 to the peripheral portion 16 of mesh 10 is at least 1.1:1 by percent weight. In embodiments, the ratio may be from about 20:1 to about 2:1, and in some embodiments, from about 10:1 to about 5:1.
  • the mesh of the present disclosure allows for the specific delivery of the bioactive agent while still providing the surgeon with the ability to customize the size of the mesh based on the anatomical need of the patient by maintaining the majority of the bioactive agent dosing in the central portion of the device. The surgeon may still trim the edges or peripheral portions of the mesh without affecting the total drug payload. Moreover, because the majority of the bioactive agent dosing is in the central portion of the device, a variety of different meshes can be manufactured using the same drug loading specification.
  • a select portion of a surface of a mesh may be drug-loaded thereby providing areas of the mesh without drug-loading (bioactive agents) as illustrated, for example, in FIGURE 2 .
  • Mesh 20 includes central portion 24, intermediate portion 28, and peripheral portion 26.
  • the central portion 24 has a higher concentration of bioactive agent 22 than the intermediate portion 28, and the peripheral portion 26 is not coated with any bioactive agent 22. This configuration would potentially allow the surgeon to cut the mesh 20 without affecting any of the drug payload.
  • the portion of the mesh to be drug-loaded and the surrounding low dose or uncoated area may vary in size or pattern depending upon a number of factors, such as the amount of drug to be loaded, the size of the mesh, and the amount of mesh which may be removed prior to implantation by the surgeon, for example.
  • the bioactive agent may also be disposed in a radially, discontinuous gradient from a higher concentration to a lower concentration as illustrated in FIGURES 3 and 4 .
  • bioactive agent 32 is distributed on mesh 30 to form a concentration gradient which includes a higher concentration about the central portion 34 of mesh 30 and a lower concentration in a predefined section 38a of intermediate portion 38 extending away from the central portion 34.
  • the central portion 34 and intermediate portion 38 are divided by a portion of mesh 30 which does not contain a bioactive agent.
  • the bioactive agent 32 is concentrated in the central portion 34 and has a decreased concentration in the section 38a of intermediate portion 38, such that the gradient distribution is decreased stepwise.
  • central portion 34 may include 150 mg of bupivacaine, while section 38a may be formulated to include 75 mg of bupivacaine.
  • central portion 34 and section 38a may both equal 25cm 2 .
  • Central portion 34 may include 500 mg of a bioactive agent, while section 38a includes 350 mg of a bioactive agent. Adjusted for surface area, the payload for central portion 34 is 500mg/25cm 2 or 20 mg/ cm 2 . Similarly, the payload for section 38a is 350mg/25cm 2 or 14 mg/cm 2 . It should be understood that these payloads are non-limiting and exemplary.
  • FIGURE 4 illustrates a radially extending, discontinuous concentration gradient decreasing from the central portion 44 through successive sections 48a, 48b, 48c, and 48d of intermediate portion 48 toward the peripheral portion 46 of mesh 40.
  • sections 38a as well as 48a, 48b, 48c, and 48d of intermediate portions 38 and 48 are annular rings extending around central portions 34 and 44.
  • the bioactive agent may be incorporated in the mesh in discontinuous rings and/or section of the mesh, and further that portions of the mesh may or may not include at least one bioactive agent.
  • the sections which include at least one bioactive agent can have any configuration extending through the intermediate portion as contemplated by those skilled in the art.
  • Each bioactive agent containing portion may include different types of bioactive agents in different combinations and amounts.
  • the central portion 44 and successive sections 48a, 48b, 48c, and 48d of intermediate portion 48 of FIGURE 4 may uniformly include decreasing amounts of a single or multiple bioactive agents.
  • the central portion 44 may include a high concentration of one or more bioactive agents that decreases through a select number of sections of intermediate portion 48 (e.g., through section 48c) and one or more other bioactive agents that decreases in concentration through only the intermediate portion 48 (e.g., from sections 48a through 48d).
  • the bioactive agents may be disposed only through segments of the bioactive agent containing portions (e.g., one bioactive agent may be disposed on one half of the mesh and a second bioactive agent is disposed on the other half of the mesh). It should be understood that various combinations of bioactive agents and placement thereof on the medical device may be utilized in accordance with the present disclosure.
  • any portion of the mesh may include any number, size and shape of gradient coatings.
  • the bioactive agent 52 may be applied in any shape to the mesh 50 so long as the concentration gradient of the bioactive agent tapers from the central portion 54 towards the peripheral portion 56 of the mesh 50.
  • Mesh 50 includes a central portion 54 having the highest concentration of bioactive agent 52 and successive section 58a, 58b, 58c, and 58d in the form of bands which extend longitudinally along the length "L" of the mesh 50 and laterally outward from the central portion 54.
  • Each section 58a, 58b, 58c, and 58d include successively lower concentrations of bioactive agent 52 as they extend toward peripheral portion 56.
  • the bioactive agent may be applied to the mesh as a coating composition, film, or foam as described above.
  • a composition including a bioactive agent and a suitable solvent may be sprayed onto the mesh in successive coatings to form the concentration gradient along a portion of a surface thereof.
  • microspheres of a bioactive agent may be embedded within a polymeric material and cured to form a film which may be applied to the mesh.
  • a bioactive agent may be contained within or coated thereon a lyophilized foam which may be applied to the mesh.
  • the bioactive agent may be contained within the fibers or filaments of the mesh, for example, by compounding a suitable bioactive agent within the polymer resin.
  • the mesh may also include a bioactive agent 62 having a concentration gradient in the height dimension "H" of the mesh 60.
  • a film 61 containing bioactive agent 62 is formed over mesh 60.
  • the attached surface "a" of the film 61 contains a high concentration of bioactive agent 62 which decreases towards free surface "s.”
  • the free surface "s” of film 61 may have a high concentration of bioactive agent 62 which decreases toward the attached surface "a.”
  • the film 61 may have a high concentration in the center which decreases towards both the free surface "s” and the attached surface "a.”
  • the pores or openings formed in the medical device itself may be utilized for deposition of the bioactive agent thus creating a concentration gradient in the height dimension.
  • the bioactive agent 72 may be encapsulated within a polymeric material in a flowable, or non-solid, state and applied to the mesh 70.
  • Mesh 70 includes a central portion 74 including a dried coating, film, or foam of bioactive agent disposed thereon as described above.
  • the intermediate portion 78 of mesh 70 is a discontinuous belt of polymeric capsules 79 containing bioactive agent 72.
  • the polymeric capsules 79 may be a pocket or patch of polymeric material containing a reservoir of bioactive agent in solution, gel, particulate, or foam forms.
  • the polymeric pocket or patch may be composed of a rapidly bioerodible polymer for quick degradation and release of the bioactive agent, or may be breakable via an external force for release of the bioactive agent.
  • the polymeric capsules 79 may aid the surgeon in visualization of the mesh, as well as placement of fasteners, such as tacks or sutures, to fixate the mesh.
  • the polymeric capsules 79 are penetrated with a surgical fastener, thereby rapidly releasing the bioactive agent onto the surrounding tissue providing immediate therapeutic relief.
  • the polymeric capsules 79 may be filled with anesthetics to aid in controlling pain upon mesh fixation.
  • the anesthetics may be used in combination with antiseptics or antibiotics to aid in preventing/treating post-attachment infection, with anti-inflammatories to aid in preventing/treating post-attachment swelling, or with other medicaments as is within the purview of those skilled in the art.
  • the polymeric capsules 79 will allow the surgeon to more easily orientate the mesh within the surgical site, properly fasten the mesh against the tissue, and decrease the pain or discomfort associated with fastening the mesh by providing immediate medication to the site.
  • the portions of the mesh which contain or are coated with bioactive agent(s) may be clearly marked on the mesh itself for visualization by the surgeon. These markings may be applied by utilizing ink that may be visualized under visible, infrared, ultraviolet, and/or by other wavelengths of light.
  • the meshes may also be marked with orientation lines, making it easy for the surgeon to orient the mesh relative to both the center of the mesh and the location of drug loading.
  • the orientation lines may be solid or dotted/dashed lines, curves, or other written indicia. These markings may be linear or concentric in nature and can be identified by distance measurements (e.g., 1/8 inch, cm, or mm), location measurements (e.g., north, east, south west), and/or positioning markings (e.g., arrows, text).
  • the gradient of bioactive agent used to coat the medical device according to the present disclosure may vary.
  • the concentration gradient may increase from the peripheral portions 116 to the central portion 114 of the mesh.
  • the lower concentration of a first bioactive agent disposed in the central portion 114 may be more therapeutically effective compared to a higher concentration of a second bioactive agent disposed in the peripheral portions 116.
  • the peripheral portion may include a first bioactive agent, which is different from a second bioactive agent disposed in the central portion 114.
  • the concentration gradient may also increase across the surface of the mesh from one side to another (e.g., left to right, top to bottom, corner to corner, etc.).
  • concentrations of bioactive agents may be positioned along any portion of the mesh. Other variations are also within the purview of those skilled in the art.
  • the medical devices described herein may further include a plurality of concentration gradients.
  • a single bioactive agent may be disposed on the medical device in a manner wherein the concentration of the agent increases and decreases more than once across the surface of the device.
  • a plurality of bioactive agents may be disposed across the implant wherein each bioactive agent represents a different concentration gradient.
  • a first bioactive agent may be disposed to create a continuous concentration gradient and a second bioactive agent may be disposed to create a discontinuous concentration gradient.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Surgery (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Materials Engineering (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
EP11250117.6A 2010-02-03 2011-02-02 Charge différentielle de dispositifs médicaux pour élution de médicaments Active EP2353618B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30100710P 2010-02-03 2010-02-03
US12/987,259 US9216240B2 (en) 2010-02-03 2011-01-10 Differential loading of drug-eluting medical devices

Publications (3)

Publication Number Publication Date
EP2353618A2 true EP2353618A2 (fr) 2011-08-10
EP2353618A3 EP2353618A3 (fr) 2014-07-09
EP2353618B1 EP2353618B1 (fr) 2018-07-18

Family

ID=44169216

Family Applications (1)

Application Number Title Priority Date Filing Date
EP11250117.6A Active EP2353618B1 (fr) 2010-02-03 2011-02-02 Charge différentielle de dispositifs médicaux pour élution de médicaments

Country Status (5)

Country Link
US (1) US9216240B2 (fr)
EP (1) EP2353618B1 (fr)
JP (1) JP2011156355A (fr)
AU (1) AU2011200316B2 (fr)
CA (1) CA2728324A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2882466A4 (fr) * 2012-08-13 2016-04-27 Covidien Lp Dispositif poreux implantable comprenant un film
US10632207B2 (en) 2009-02-21 2020-04-28 Sofradim Production Compounds and medical devices activated with solvophobic linkers
WO2022146717A1 (fr) * 2020-12-30 2022-07-07 Covidien Lp Implants chirurgicaux comprenant des repères

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2985171B1 (fr) * 2011-12-29 2014-06-06 Sofradim Production Prothese pour hernie avec moyen de marquage
US11065368B2 (en) * 2013-03-15 2021-07-20 Cook Biotech Incorporated Drug eluting graft constructs and methods
US20150351889A1 (en) * 2014-06-05 2015-12-10 Vivex Biomedical Inc. Dynamic Biometric Mesh
DE102015013989A1 (de) * 2015-10-30 2017-05-04 Johnson & Johnson Medical Gmbh Chirurgisches Implantat
KR101883737B1 (ko) * 2016-12-26 2018-07-31 (주) 태광직물 캡사이신 오일 캡슐을 포함하는 밴딩용 점착제 조성물 및 그를 포함하는 스포츠테이핑용 기능성 밴드
CN111840648B (zh) * 2016-12-28 2022-03-25 广州迈普再生医学科技股份有限公司 多层复合组织修复补片及其制备方法
US10874498B2 (en) * 2017-09-06 2020-12-29 Tepha, Inc. Calendered surgical meshes comprising polyhydroxyalkanoates
CN108014414B (zh) * 2018-01-05 2019-10-18 清华大学 一种植入式可降解药物缓释电子贴片的制备方法
CN211187654U (zh) * 2018-03-01 2020-08-07 C.R.巴德公司 用于修复软组织缺陷的可植入假体以及组合体

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998051290A2 (fr) * 1997-05-16 1998-11-19 Children's Medical Center Corporation Formulations anesthesiques locales
JP4859317B2 (ja) 1999-08-06 2012-01-25 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 薬剤放出生分解性繊維インプラント
GB0108088D0 (en) 2001-03-30 2001-05-23 Browning Healthcare Ltd Surgical implant
US7056338B2 (en) 2003-03-28 2006-06-06 Conor Medsystems, Inc. Therapeutic agent delivery device with controlled therapeutic agent release rates
US20030175410A1 (en) * 2002-03-18 2003-09-18 Campbell Phil G. Method and apparatus for preparing biomimetic scaffold
US20040019360A1 (en) 2002-07-25 2004-01-29 Farnsworth Ted R. Tissue repair device with a removable support member
US20050010170A1 (en) 2004-02-11 2005-01-13 Shanley John F Implantable medical device with beneficial agent concentration gradient
US20040253185A1 (en) 2003-06-12 2004-12-16 Atrium Medical Corp. Medicated ink
US20060246109A1 (en) 2005-04-29 2006-11-02 Hossainy Syed F Concentration gradient profiles for control of agent release rates from polymer matrices
US7351423B2 (en) 2004-09-01 2008-04-01 Depuy Spine, Inc. Musculo-skeletal implant having a bioactive gradient
US8652504B2 (en) 2005-09-22 2014-02-18 Medivas, Llc Solid polymer delivery compositions and methods for use thereof
US8506582B2 (en) 2005-10-25 2013-08-13 Ethicon, Inc. Template for surgical meshes
US7935364B2 (en) 2008-03-04 2011-05-03 Wisconsin Alumni Research Foundation Patterned gradient wound dressing and methods of using same to promote wound healing
US9744123B2 (en) * 2009-06-30 2017-08-29 Kensey Nash Corporation Biphasic implant device providing gradient

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10632207B2 (en) 2009-02-21 2020-04-28 Sofradim Production Compounds and medical devices activated with solvophobic linkers
EP2882466A4 (fr) * 2012-08-13 2016-04-27 Covidien Lp Dispositif poreux implantable comprenant un film
WO2022146717A1 (fr) * 2020-12-30 2022-07-07 Covidien Lp Implants chirurgicaux comprenant des repères

Also Published As

Publication number Publication date
CA2728324A1 (fr) 2011-08-03
EP2353618A3 (fr) 2014-07-09
US9216240B2 (en) 2015-12-22
US20110189270A1 (en) 2011-08-04
JP2011156355A (ja) 2011-08-18
EP2353618B1 (fr) 2018-07-18
AU2011200316B2 (en) 2015-04-02
AU2011200316A1 (en) 2011-08-18

Similar Documents

Publication Publication Date Title
EP2353618B1 (fr) Charge différentielle de dispositifs médicaux pour élution de médicaments
US20210189616A1 (en) Gripping fabric coated with a bioresorbable impenetrable layer
AU2010226888B2 (en) Mesh implant
JP5424582B2 (ja) バットレスおよび外科用ステープル止め装置
EP2374418B1 (fr) Dispositif médical à crans et son procédé de fabrication.
US20200246167A1 (en) Bioresorbable Biopolymer Stent
CN103874465A (zh) 具有可溶胀抓紧部件的可植入装置
EP2368524A2 (fr) Pièce pour hernie
JP2011161231A (ja) 迅速な創傷閉鎖のための減圧パッチ
CA2672496A1 (fr) Implants medicaux avec une combinaison de paclitaxel et de dipyridamole
KR102249720B1 (ko) 필름 및 제조 방법
US20150073445A1 (en) Implantable Porous Device Including a Film
EP2476444A2 (fr) Dispositif médical avec films intra-poreux
EP2540324A2 (fr) Matériaux biodégradables pour dispositifs orthopédiques basés sur des stéréocomplexes de polymère
KR20160004984A (ko) 생체적합성 고분자 물질 및 흉터형성 억제약물을 포함하는 의료장치 코팅 제형

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: COVIDIEN LP

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RIC1 Information provided on ipc code assigned before grant

Ipc: A61L 27/54 20060101ALI20140602BHEP

Ipc: A61L 31/16 20060101ALI20140602BHEP

Ipc: A61L 15/44 20060101AFI20140602BHEP

17P Request for examination filed

Effective date: 20150105

RBV Designated contracting states (corrected)

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20170419

RIC1 Information provided on ipc code assigned before grant

Ipc: A61L 27/54 20060101ALI20171117BHEP

Ipc: A61L 31/16 20060101ALI20171117BHEP

Ipc: A61L 15/44 20060101AFI20171117BHEP

Ipc: A61F 2/00 20060101ALI20171117BHEP

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20180207

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1018674

Country of ref document: AT

Kind code of ref document: T

Effective date: 20180815

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602011050118

Country of ref document: DE

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20180718

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1018674

Country of ref document: AT

Kind code of ref document: T

Effective date: 20180718

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180718

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181018

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181019

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181018

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180718

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180718

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180718

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180718

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181118

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180718

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180718

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180718

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180718

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180718

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180718

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602011050118

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180718

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180718

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180718

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180718

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180718

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180718

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180718

26N No opposition filed

Effective date: 20190423

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180718

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190202

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180718

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20190228

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190228

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190228

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190228

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180718

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190202

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181118

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IE

Payment date: 20210122

Year of fee payment: 11

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180718

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20210120

Year of fee payment: 11

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20110202

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180718

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20220202

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220202

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220202

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20240123

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20240123

Year of fee payment: 14